Chemokines

Recombinant Human BCA-1 (CXCL13)

Product Details

Catalogue Number: 300-47
Description:
Recombinant Human BCA-1 (CXCL13)

BCA-1/BLC, a CXC chemokine, is expressed in the liver, spleen, lymph nodes, appendix and stomach. It exerts its activities through its only receptor, CXCR5. BCA-1/BLC is a potent chemoattractant for B lymphocytes, and induces weak chemotactic response in T cells and macrophages. It manifests no activity on neutrophils and monocytes. Recombinant Human BCA-1 is a 10.3 kDa protein containing 87 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines.

Source: E.coli

Synonyms: B cell Attracting Chemokine-1, CXCL13, BLC (mouse), BLR1 Ligand

AA Sequence: VLEVYYTSLR CRCVQESSVF IPRRFIDRIQ ILPRGNGCPR KEIIVWKKNK SIVCVDPQAE WIQRMMEVLR KRSSSTLPVP VFKRKIP

Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses.

Biological Activity: Determined by its ability to chemoattract human B cells using a concentration range of 1.0-10.0 ng/ml.

Calculated Molecular Weight: 10.3 kDa

Accession Number: O43927

Gene ID: 10563

crossreactivity:
Country Of Origin: USA

Not for human use.

Research Interest

product.subtitle.recentcitations

First Author
Seda, V
Title
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Citation
Blood; 138(9) pg758-772
PubMed Id
First Author
Gimenez, N
Title
Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
Citation
Scientific Reports; 10(1) pg22153
PubMed Id
First Author
Yasuoka, H
Title
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
Citation
Scientific Reports; 10(1) pg10377
PubMed Id

product.subtitle.productreviews

Existing reviews
For migration assay
We have been using this chemokine to test the ability of our cells to migrate and we always get really good results when working with PBMCs. Highly recommended.
From:  Jhomary | Date:  8/26/2020